SynthesisFrontiers in medicine2021
Effects of SGLT2 Inhibitors on Renal Outcomes in Patients With Chronic Kidney Disease: A Meta-Analysis.
Synthesis in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 4 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Impact of SGLT2 Inhibitors on Renal Function in Type 2 Diabetic Patients with Coronary Artery Disease Undergoing Percutaneous Intervention: A Systematic Review and Meta-Analysis.Current diabetes reviews · 2025Pooled it
- The Efficacy and Safety of SGLT2 Inhibitors in Diabetes Kidney Transplant Recipients: A Systematic Review and Meta-Analysis.F1000Research · 2025Pooled it
- Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes.The Cochrane database of systematic reviews · 2024Pooled it
- Impact of Chronic Kidney Disease on Outcomes of Percutaneous Coronary Intervention in Patients With Diabetes Mellitus: A Systematic Review and Meta-Analysis.Texas Heart Institute journal · 2023Pooled it
- Review
- Renal Functional Reserve-Informed Personalized Renoprotection in Chronic Kidney Disease: A Proposed Extension of the KDIGO CGA Framework.Biomedicines · 2026Review
- Real-World Experience With Dapagliflozin in Non-diabetic Chronic Kidney Disease: A Case Series From India.Cureus · 2026Article
- Cluster-Defined Metabolic Heterogeneity and Longitudinal Effects of Allopurinol and SGLT2 Inhibitors in Hyperuricemic Type 2 Diabetes.Medical sciences (Basel, Switzerland) · 2026Article
- Beyond safety: adverse events and unanticipated advantages of SGLT2 inhibitors.European journal of clinical pharmacology · 2026Review
- Review
- Long-term efficacy and renal safety of SGLT2 inhibitors in patients with heart failure and advanced chronic kidney disease (stage 4): a propensity score-matched retrospective cohort study.Frontiers in cardiovascular medicine · 2026Article
- Metabolic syndrome and kidney dysfunction: emerging molecular and cellular mechanisms at the metabolic-renal interface.Frontiers in endocrinology · 2026Review
- Beneficial effect of sodium-glucose cotransporter 2 inhibitors on kidney function can be just a mirage.World journal of nephrology · 2025Review
- Bibliometric analysis of research hotspots and trends of type 2 diabetes mellitus and sodium-glucose cotransporter-2 inhibitors.Journal of family medicine and primary care · 2025Review
- Hypertension and Diabetes as Determinants of Patient-Reported Quality of Life in Permanent Atrial Fibrillation.Diagnostics (Basel, Switzerland) · 2025Article
- Repurposing Diabetes Therapies in CKD: Mechanistic Insights, Clinical Outcomes and Safety of SGLT2i and GLP-1 RAs.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Evaluating the overall renal outcomes of sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with chronic kidney disease (CKD).Diabetology & metabolic syndrome · 2025Review
- Hypoglycemic agents and bone health; an umbrella systematic review of the clinical trials' meta-analysis studies.Diabetology & metabolic syndrome · 2024Review
- Plasma matrix metalloproteinases and tissue inhibitors of metalloproteinases explored in relation to the severity and progression of diabetic retinopathy in patients with type 1 diabetes: baseline and prospective analyses.BMJ open ophthalmology · 2024Article
- Chronic Kidney Disease in Brazil: Current Status and Recommended Improvements.Kidney diseases (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.